EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of Serum microRNA Profiles on the Progression‐Free Survival of Patients With High‐Grade Serous Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Takashi Uehara iD, Juntaro Matsuzaki iD, Yusuke Yamamoto iD, Hiroshi Yoshida iD, Yuto Ogawa iD, Junichiro Miura iD, Hitoshi Fujimiya iD, Satoko Takizawa iD, Akira Yokoi iD, Kan Yonemori iD, Ken Kato iD, Mitsuya Ishikawa iD und 1 weitere

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Takashi Uehara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Neoadjuvant Therapy, MicroRNAs, Cystadenocarcinoma, Serous. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Japan Agency for Medical Research and a Development and New Energy and Industrial Technology Development Organization and JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

High‐grade serous ovarian cancer is a deadly cancer with a poor prognosis. Serum microRNAs have been used to detect and diagnose various cancers. We aimed to investigate the prognostic impact of serum microRNA profiles pre‐, peri‐, and post‐primary treatment on the progression‐free survival of patients with advanced high‐grade serous ovarian cancer receiving neoadjuvant chemotherapy.

Methods

Patients were prospectively recruited, and pre‐, peri‐, and post‐treatment blood samples were collected. MicroRNA microarray results, together with the clinical and surgical data, were analyzed using Cox regression with leave‐one‐out least absolute shrinkage and selection operator for progression‐free survival.

Results

Overall, 29 patients were included. A combined analysis of pre‐treatment serum microRNAs and clinical factors showed a higher c‐index (0.86) for distinguishing high‐ and low‐risk groups for poor progression‐free survival outcomes compared to analyzing each factor alone (0.70 and 0.64, respectively). The high‐risk group exhibited significantly worse progression‐free survival (log‐rank, p < 0.01). The serum microRNA profile at 3 months post‐treatment showed outstanding discrimination (c‐index of 1.00). Changes in the microRNA profile between pre‐ and peri‐treatment had no prognostic impact; however, the difference between pre‐treatment and 3 months post‐treatment exhibited excellent discrimination (c‐index of 1.00).

Conclusions

In patients with advanced high‐grade serous ovarian cancer who received neoadjuvant chemotherapy, a combination of the pre‐treatment serum microRNA profiles and clinical factors, or the 3‐month post‐treatment serum microRNA profile could distinguish between those in high‐ and low‐risk groups for poor progression‐free survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsNeoadjuvant TherapyMicroRNAsCystadenocarcinoma, SerousBiomarkers, TumorHumansFemaleProgression-Free SurvivalPrognosisMiddle AgedAdultAged

Stichwörter der Autor:innen

biomarkerscirculating microRNAneoadjuvant therapyovarian neoplasmsprognosis

Substanzen

MicroRNAsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Chiba University Hospital, Chiba, Japan.
  • Division of Interdisciplinary Genetics and Nanomedicine, Research Center for Drug Discovery, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
  • Dynacom Co. Ltd., Chiba, Japan.

ORCID-Profile: Takashi Uehara, Juntaro Matsuzaki, Yusuke Yamamoto, Hiroshi Yoshida, Yuto Ogawa, Junichiro Miura, Hitoshi Fujimiya, Satoko Takizawa, Akira Yokoi, Kan Yonemori, Ken Kato, Mitsuya Ishikawa, Takahiro Ochiya

Förderung

  • Japan Agency for Medical Research and a Development and New Energy and Industrial Technology Development Organization and JSPS KAKENHI

Zitieren

APA

Uehara, T., Matsuzaki, J., Yamamoto, Y., Yoshida, H., Ogawa, Y., Miura, J., Fujimiya, H., Takizawa, S., Yokoi, A., Yonemori, K., Kato, K., Ishikawa, M., & Ochiya, T. (2026). Prognostic Impact of Serum microRNA Profiles on the Progression‐Free Survival of Patients With High‐Grade Serous Ovarian Cancer Receiving Neoadjuvant Chemotherapy. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70500

Vancouver

Uehara T, Matsuzaki J, Yamamoto Y, Yoshida H, Ogawa Y, Miura J, et al. Prognostic Impact of Serum microRNA Profiles on the Progression‐Free Survival of Patients With High‐Grade Serous Ovarian Cancer Receiving Neoadjuvant Chemotherapy. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70500

BibTeX
@article{Uehara2026,
  author = {Uehara, Takashi and Matsuzaki, Juntaro and Yamamoto, Yusuke and Yoshida, Hiroshi and Ogawa, Yuto and Miura, Junichiro and Fujimiya, Hitoshi and Takizawa, Satoko and Yokoi, Akira and Yonemori, Kan and Kato, Ken and Ishikawa, Mitsuya and Ochiya, Takahiro},
  title = {Prognostic Impact of Serum microRNA Profiles on the Progression‐Free Survival of Patients With High‐Grade Serous Ovarian Cancer Receiving Neoadjuvant Chemotherapy},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70500}
}
Kostenlos starten →